Carlsmed receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Metrics to compare | CARL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCARLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.9x | −1.9x | −0.2x | |
PEG Ratio | −0.23 | −0.26 | 0.00 | |
Price/Book | 6.3x | 2.4x | 2.6x | |
Price / LTM Sales | 6.7x | 3.0x | 2.6x | |
Upside (Analyst Target) | 26.3% | 170.8% | 76.9% | |
Fair Value Upside | Unlock | −0.7% | 14.9% | Unlock |
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.